Skip to main content
Erschienen in:

Open Access 13.09.2024 | Brief Report

Meningitis and intracranial abscess due to Mycoplasma pneumoniae in a B cell-depleted patient with multiple sclerosis

verfasst von: Dominik Madžar, Florian T. Nickel, Veit Rothhammer, Philipp Goelitz, Walter Geißdörfer, Roger Dumke, Roland Lang

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 11/2024

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Mycoplasma pneumoniae, a frequent respiratory pathogen, can cause neurological disease manifestations. We here present a case of M. pneumoniae as cause of meningitis and occurrence of an intracranial abscess as a complication of mastoiditis with septic cerebral venous sinus thrombosis in a patient with multiple sclerosis on anti-CD20 therapy.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Case description

A 21-year-old female with a history of multiple sclerosis (MS) since 2017 was treated with rituximab (RTX) until 2018 and with ocrelizumab (OCR) thereafter (last dose January 2020). In March 2020, routine MRI showed bilateral mastoiditis, left sternocleidomastoid muscle abscess, and thrombosis of the right sigmoid sinus and right internal jugular vein. Bacteriological cultures from the abscesses and mastoids were sterile, except for skin commensals. Two months later, the patient developed fever and headaches. MRI showed contrast enhancement in the right internal jugular vein and sigmoid sinus (Fig. 1A, [27 Jun 2020]). Cerebrospinal fluid (CSF) analysis findings were consistent with bacterial infection (CSF findings detailed in Table 1). Bacteriological and fungal CSF cultures, as well as 16S rDNA PCR, were negative. Despite multiple antibiotic treatment attempts in the following weeks (including ceftriaxone, piperacillin/tazobactam, meropenem, vancomycin, linezolid, and short courses of clarithromycin, fosfomycin, and doxycycline), the patient’s clinical condition worsened. An FDG-PET yielded pathological FDG uptake only in the right internal jugular vein/sigmoid sinus. A thrombus specimen acquired through catheter angiography from the internal jugular vein was negative by microbiological culture and in 16S rDNA PCR. An MRI for new mild right facial palsy showed a new abscess formation in the right cerebellopontine angle (Fig. 1B, [25 Aug 2020]). The 16S rDNA PCR was positive from a new CSF sample obtained as a consequence of the MRI (7 weeks after the first lumbar puncture), and sequencing of the amplicon identified Mycoplasma pneumoniae. This finding was confirmed using M. pneumoniae-specific primers for real-time PCR, yielding a threshold cycle (Ct) value of 29.9. Re-analysis of the earlier CSF samples and of the internal jugular vein thrombus, which had been negative in 16S rDNA PCR, demonstrated the presence of M. pneumoniae DNA already in the first CSF sample, albeit the late Ct values indicated a much lower bacterial burden. Based on this finding, doxycycline was started. The patient improved clinically and became afebrile. Notably, the patient had already received doxycycline at the beginning of treatment, but only for a few days. Control MRIs revealed gradual abscess regression (Fig. 1C), CSF parameters improved. With a negative PCR result for M. pneumoniae DNA in the control CSF analysis and stable MRI findings, doxycycline was discontinued after 151 days. Within 4 weeks the fever recurred. CSF analysis revealed resurgence of even worse infection. MRI confirmed recurrence of leptomeningitis. Doxycycline was restarted in an increased dose (400 mg/d) and levofloxacin was added (1,000 mg/d), resulting in improvement in clinical condition, CSF findings, and MRI. Because of phototoxic skin reaction and worsening of kidney function, the doses of doxycycline and levofloxacin were reduced (200 mg/d and 250 mg/d, respectively). The antibiotic treatment has since been continued as permanent therapy. Neurological examination at the last follow-up visit (May 2023) revealed minor deficits attributable to previous MS lesions and polyneuropathy, most likely after linezolid treatment. Otherwise, the patient was doing well and was leading a normal life.
Table 1
Summary of CSF findings
https://static-content.springer.com/image/art%3A10.1007%2Fs10096-024-04935-3/MediaObjects/10096_2024_4935_Tab1_HTML.png
The table summarizes the CSF findings A) prior to the identification of the causative pathogen, B) after initiation of doxycycline treatment (= phase of marked clinical improvement), C) after discontinuation of doxycycline treatment (= phase of recurrence of fever and clinical deterioration), and D) after resumption of doxycycline and additional levofloxacin treatment. Pathological CSF findings are shown in a color gradient, with increasing shades of red indicating greater deviation from normal values and increasing shades of yellow indicate less deviation from normal values. Normal values and negative PCR results are highlighted in green. *) Missing values because serum glucose was not measured at time of the lumbar puncture. **) Not measured

Discussion

To the best of our knowledge, we report the first case of meningitis as a complication of septic sinus thrombosis after mastoiditis caused by M. pneumoniae associated with B cell depletion by RTX and OCR. We suggest that this case also documents the formation of an intracranial abscess caused by M. pneumoniae: Although we have not directly demonstrated M. pneumoniae in the abscess formation, the close proximity of the abscess to the infected, thrombotic sigmoid sinus/internal jugular vein and the regression during therapy with doxycycline strongly argues for this interpretation.
In the patient presented, B lymphocytes were undetectable in peripheral blood until 11 months after the last dose of OCR, in line with the time ranges reported in the literature [1]. B cell depletion with anti-CD20 antibodies moderately increases the risk for reactivation of HBV and Herpes zoster, particularly in patients treated for lymphoma and transplant recipients [1]. Overall, the available data suggest that OCR therapy in MS patients does not lead to increased risk of severe infection [2, 3], although the risk for herpesvirus infections was higher [1]. Individual cases of severe infections have been reported after anti-CD20 therapy, including tick-borne encephalitis virus [4] or Candidatus Neoehrlichia mikurensis [5]. The identification of M. pneumoniae in this case broadens the spectrum of infectious complications after anti-CD20-mediated B cell depletion for autoimmune diseases. Severe systemic infection by M. hominis with an abdominal abscess has been reported in a patient with hypogammaglobulinemia due to RTX maintenance therapy of Non-Hodgkin lymphoma [6]. With regard to CNS infections with related pathogens, a case was reported of a brain abscess secondary to mastoiditis caused by Ureaplasma urealyticum after combination chemotherapy and RTX for Burkitt’s lymphoma [7].
M. pneumoniae is a not infrequent cause of neurological manifestations, including encephalitis (particularly in children), meningitis, ADEM, and Guillain-Barré syndrome [8, 9]. Pathogenesis of CNS disease due to M. pneumoniae is not well understood, and may be caused by direct damage of invading bacteria, indirectly by antibody- or T cell-dependent autoimmune phenomena, or by vasculitis and thrombotic vascular occlusion.
The lag period to detection of M. pneumoniae in this case was very long, illustrating the diagnostic challenge posed by M. pneumoniae as such and in addition by the B cell depletion. As M. pneumoniae is difficult to culture, diagnosis is mostly done by serology detecting specific antibodies, which are not induced to significant levels in the patient treated with anti-CD20 antibodies. Pan-bacterial PCR for 16S rDNA were repeatedly negative, despite the confirmed low levels of M. pneumoniae DNA in retrospect by specific real-time PCR, demonstrating the limited sensitivity of the broad range 16S rDNA PCR.
Timely diagnosis of M. pneumoniae is especially important because of its intrinsic resistance to commonly used broad spectrum antibiotics targeting cell wall synthesis (i.e., of the betalactam and glycopeptide groups). Macrolides have been the drug of choice to treat M. pneumoniae for decades because of the low MIC values of wild-type strains, their overall good safety profile, and their immunomodulatory effect that may contribute to clinical improvement in M. pneumoniae infections characterized by strong immunopathology. However, macrolides do not penetrate well into the CSF and are therefore not optimal for treatment of meningoencephalitis cases [9]. In addition, there is growing resistance to macrolides among M. pneumoniae, especially in Asian countries. In Europe, macrolide-resistance is most prevalent in Italy and France (between 9 and 26%) [10], and around 3% in Germany [11]. Molecular typing of the M. pneumoniae DNA isolated from the CSF in this case showed the presence of the A2064G (corresponds to E. coli numbering A2058G) substitution in the peptidyl transferase loop of 23S rRNA, which is globally the most frequent mutation associated with resistance to macrolide antibiotics [10, 12]. Since development of macrolide-resistance during therapy has been described [12], it is possible that the intermittent treatment with clarithromycin for one week (last week of July 2020) favored the selection of this macrolide-resistant M. pneumoniae. Due to the paucity of specific DNA in the CSF samples obtained prior to therapy with clarithromycin (Ct-values 38.9/39.9), the genotyping for the A2064G mutation could not be performed.
Tetracyclines and fluoroquinolones are treatment choices for macrolide-resistant M. pneumoniae. The MIC values for both tetracyclines and fluoroquinolones are higher than for macrolides, but to date no resistance has been reported in M. pneumoniae to these groups of antibiotics. In addition, both tetracyclines and fluoroquinolones pass the blood-CSF barrier well and reach therapeutic concentrations required for treatment of meningoencephalitis [13].
Cessation of doxycycline treatment resulted in rapid recurrence and even exacerbation of infection. We hypothesized that in patient the internal jugular vein/cerebral sinus thrombus containing M. pneumoniae might serve as a reservoir and a source of bacterial spread if not permanently suppressed by antibiotic treatment. Therefore, we considered permanent treatment warranted, weighing the risks and benefits. Furthermore, the extent of CSF parameter changes we observed are not consistent with previous reports of M. pneumoniae-associated meningitis/meningoencephalitis, describing moderate CSF abnormalities [14, 15], whereas massive CSF alterations were rather linked to meningitis/meningoencephalitis caused by M. hominis [16].
In summary, this case report illustrates that under B cell depletion unusual infectious agents can lead to severe disease, potentially with unusual presentations and prolonged courses. As this therapeutic principle is increasingly used in autoimmune diseases and more drugs are approved (such as ofatumumab, inebilizumab, ublituximab), the partly atypical infectious side effect spectrum should be kept in mind.

Declarations

Competing interests

The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Literatur
2.
Zurück zum Zitat Kappos L, Li D, Calabresi PA et al (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378(9805):1779–1787CrossRefPubMed Kappos L, Li D, Calabresi PA et al (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378(9805):1779–1787CrossRefPubMed
3.
Zurück zum Zitat Hauser SL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221–234CrossRefPubMed Hauser SL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221–234CrossRefPubMed
4.
Zurück zum Zitat Steininger PA, Bobinger T, Dietrich W et al (2017) Two cases of severe tick-borne encephalitis in rituximab-treated patients in germany: implications for diagnosis and prevention. Open Forum Infect Dis 4(4):ofx204CrossRefPubMedPubMedCentral Steininger PA, Bobinger T, Dietrich W et al (2017) Two cases of severe tick-borne encephalitis in rituximab-treated patients in germany: implications for diagnosis and prevention. Open Forum Infect Dis 4(4):ofx204CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Grankvist A, Andersson PO, Mattsson M et al (2014) Infections with the tick-borne bacterium “Candidatus Neoehrlichia mikurensis” mimic noninfectious conditions in patients with B cell malignancies or autoimmune diseases. Clin Infect Dis 58(12):1716–1722CrossRefPubMed Grankvist A, Andersson PO, Mattsson M et al (2014) Infections with the tick-borne bacterium “Candidatus Neoehrlichia mikurensis” mimic noninfectious conditions in patients with B cell malignancies or autoimmune diseases. Clin Infect Dis 58(12):1716–1722CrossRefPubMed
6.
Zurück zum Zitat Nulens E, Van Praet J, Selleslag D et al (2016) A disseminated Mycoplasma hominis infection in a patient with an underlying defect in humoral immunity. Infection 44(3):379–381CrossRefPubMed Nulens E, Van Praet J, Selleslag D et al (2016) A disseminated Mycoplasma hominis infection in a patient with an underlying defect in humoral immunity. Infection 44(3):379–381CrossRefPubMed
7.
Zurück zum Zitat Deetjen P, Maurer C, Rank A, Berlis A, Schubert S, Hoffmann R (2014) Brain abscess caused by Ureaplasma urealyticum in an adult patient. J Clin Microbiol 52(2):695–698CrossRefPubMedPubMedCentral Deetjen P, Maurer C, Rank A, Berlis A, Schubert S, Hoffmann R (2014) Brain abscess caused by Ureaplasma urealyticum in an adult patient. J Clin Microbiol 52(2):695–698CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Britton PN, Dale RC, Blyth CC et al (2020) Causes and clinical features of childhood encephalitis: a multicenter. Prospective Cohort Study Clin Infect Dis 70(12):2517–2526PubMed Britton PN, Dale RC, Blyth CC et al (2020) Causes and clinical features of childhood encephalitis: a multicenter. Prospective Cohort Study Clin Infect Dis 70(12):2517–2526PubMed
9.
Zurück zum Zitat D’Alonzo R, Mencaroni E, Di Genova L, Laino D, Principi N, Esposito S (2018) Pathogenesis and treatment of neurologic diseases associated with mycoplasma pneumoniae infection. Front Microbiol 9:2751CrossRefPubMedPubMedCentral D’Alonzo R, Mencaroni E, Di Genova L, Laino D, Principi N, Esposito S (2018) Pathogenesis and treatment of neurologic diseases associated with mycoplasma pneumoniae infection. Front Microbiol 9:2751CrossRefPubMedPubMedCentral
10.
12.
Zurück zum Zitat Dumke R, Stolz S, Jacobs E, Juretzek T (2014) Molecular characterization of macrolide resistance of a Mycoplasma pneumoniae strain that developed during therapy of a patient with pneumonia. Int J Infect Dis 29:197–199CrossRefPubMed Dumke R, Stolz S, Jacobs E, Juretzek T (2014) Molecular characterization of macrolide resistance of a Mycoplasma pneumoniae strain that developed during therapy of a patient with pneumonia. Int J Infect Dis 29:197–199CrossRefPubMed
13.
Zurück zum Zitat Nau R, Sörgel F, Eiffert H (2010) Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 23(4):858–883CrossRefPubMedPubMedCentral Nau R, Sörgel F, Eiffert H (2010) Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 23(4):858–883CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Socan M, Ravnik I, Bencina D, Dovc P, Zakotnik B, Jazbec J (2001) Neurological symptoms in patients whose cerebrospinal fluid is culture- and/or polymerase chain reaction-positive for Mycoplasma pneumoniae. Clin Infect Dis 32(2):E31–E35CrossRefPubMed Socan M, Ravnik I, Bencina D, Dovc P, Zakotnik B, Jazbec J (2001) Neurological symptoms in patients whose cerebrospinal fluid is culture- and/or polymerase chain reaction-positive for Mycoplasma pneumoniae. Clin Infect Dis 32(2):E31–E35CrossRefPubMed
15.
Zurück zum Zitat Sarathchandran P, Al Madani A, Alboudi AM, Inshasi J (2018) Mycoplasma pneumoniae infection presenting as stroke and meningoencephalitis with aortic and subclavian aneurysms without pulmonary involvement. BMJ Case Rep 2018. https://doi.org/10.1136/bcr-2017-221831 Sarathchandran P, Al Madani A, Alboudi AM, Inshasi J (2018) Mycoplasma pneumoniae infection presenting as stroke and meningoencephalitis with aortic and subclavian aneurysms without pulmonary involvement. BMJ Case Rep 2018. https://​doi.​org/​10.​1136/​bcr-2017-221831
16.
Zurück zum Zitat Dong Y, He Y, Zhou X et al (2022) Diagnosis of mycoplasma hominis meningitis with metagenomic next-generation sequencing: a case report. Infect Drug Resist 15:4479–4486CrossRefPubMedPubMedCentral Dong Y, He Y, Zhou X et al (2022) Diagnosis of mycoplasma hominis meningitis with metagenomic next-generation sequencing: a case report. Infect Drug Resist 15:4479–4486CrossRefPubMedPubMedCentral
Metadaten
Titel
Meningitis and intracranial abscess due to Mycoplasma pneumoniae in a B cell-depleted patient with multiple sclerosis
verfasst von
Dominik Madžar
Florian T. Nickel
Veit Rothhammer
Philipp Goelitz
Walter Geißdörfer
Roger Dumke
Roland Lang
Publikationsdatum
13.09.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 11/2024
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-024-04935-3

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Urintest auf Prostatakrebs funktioniert mit Erststrahlurin

Ein auf die Expression von 18 Genen gestützter Urintest auf klinisch signifikanten Prostatakrebs könnte offenbar auch in Anwendung auf Erststrahlurin dazu dienen, unnötige Biopsien zu vermeiden.

Vier-Punkte-Regel zum Abbruch der Reanimation

Für die Beendigung von Wiederbelebungsmaßnahmen nach Herzstillstand in Kliniken schlägt ein internationales Team eine Vier-Punkte-Regel vor. Deren Zuverlässigkeit wurde in einer skandinavischen Kohortenstudie validiert.

Hilft eine Metaanalyse, die Kortison-Kontroverse bei Lungenentzündung beizulegen?

Eine aufwendige Re-Analyse von randomisierten kontrollierten klinischen Studien liefert Hinweise darauf, wer – und wer eher nicht – bei einer ambulant erworbenen Pneumonie (CAP) von Glukokortikoiden profitieren könnte. Entscheidend ist demnach der Entzündungsmarker CRP.

Perioperative Chemotherapie bei Ösophaguskarzinom die bessere Strategie

Für die multimodale Therapie des resezierbaren, lokal fortgeschrittenen Adenokarzinoms des Ösophagus stehen in der aktuellen Leitlinie zwei Strategien gleichberechtigt zur Auswahl. Nach den Ergebnissen der deutschen ESOPEC-Studie sollte zukünftig der perioperativen Chemotherapie der Vorzug gegeben werden.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.